- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon Pharma Limited has received final approvals from the U.S. FDA for its ANDAs for Lenalidomide Capsules in multiple strengths (2.5 mg to 25 mg) and Dasatinib Tablets in various strengths (20 mg to 140 mg). These drugs are significant in treating multiple myeloma and certain types of leukemia. Additionally, Biocon Pharma obtained a tentative approval for Rivaroxaban Tablets (2.5 mg to 20 mg), used to manage risks associated with deep vein thrombosis and atrial fibrillation. These regulatory approvals enhance Biocon’s portfolio of complex drug products, indicating a positive outlook for future revenue growth and market expansion. Investors should watch closely for the effects of these approvals on market positioning and overall business performance.